Press Releases on May 31, 2024 - EIN Presswire - Press Release Distribution Service

Published on May 31, 2024 - 14:36 GMT

Human medicines European public assessment report (EPAR): Dasatinib Accord Healthcare, dasatinib, Status: Opinion

On 30 May 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Zegalogue, intended for the treatment of severe hypoglycaemia in patients …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on May 31, 2024 - 14:36 GMT

Human medicines European public assessment report (EPAR): Durveqtix, fidanacogene elaparvovec, Status: Opinion

On 30 May 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional1 marketing authorisation for the medicinal product Durveqtix, intended for the treatment of severe and …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on May 31, 2024 - 14:36 GMT

Human medicines European public assessment report (EPAR): Fluenz, influenza vaccine (live attenuated, nasal), Status: Opinion

On 21 May 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Fluenz, intended for the prevention of influenza disease in children and …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on May 31, 2024 - 14:36 GMT

Human medicines European public assessment report (EPAR): GalliaPharm, Gallium (68Ga) chloride,Germanium (68Ge) chloride, Status: ...

On 30 May 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product GalliaPharm, a radionuclide generator. GalliaPharm is not intended for …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on May 31, 2024 - 14:36 GMT

Human medicines European public assessment report (EPAR): Ixchiq, Chikungunya vaccine (live), Status: Opinion

On 30 May 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Ixchiq, intended for the prevention of chikungunya disease in adults 18 …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on May 31, 2024 - 14:36 GMT

Human medicines European public assessment report (EPAR): Apexelsin, paclitaxel, Status: Opinion

On 30 May 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Apexelsin, intended for the treatment of metastatic breast cancer, …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on May 31, 2024 - 14:36 GMT

Global Value Web (GVW) announces ODHSI India first Sciences Symposium: Mumbai, October 5th 2024

MUMBAI, INDIA, May 31, 2024 /⁨EINPresswire.com⁩/ -- Global Value Web (GVW) and OHDSI India Chapter (pronounced Odyssey) are proud to announce this first-of-its-kind symposium in India, focused on Observational Health Data sciences and Informatics; OHDSI. …

Distribution channels: Consumer Goods, Culture, Society & Lifestyle ...

Published on May 31, 2024 - 14:36 GMT

Human medicines European public assessment report (EPAR): Avzivi, bevacizumab, Status: Opinion

On 30 May 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Avzivi, intended for the treatment of carcinoma of the colon or rectum, …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on May 31, 2024 - 14:36 GMT

Human medicines European public assessment report (EPAR): Pomalidomide Accord, pomalidomide, Status: Opinion

On 30 May 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Pomalidomide Accord, intended for the treatment of multiple myeloma. The …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on May 31, 2024 - 14:36 GMT

Human medicines European public assessment report (EPAR): Pomalidomide Zentiva, pomalidomide, Status: Opinion

On 30 May 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Pomalidomide Zentiva, intended for the treatment of multiple myeloma. The …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on May 31, 2024 - 14:36 GMT

Human medicines European public assessment report (EPAR): Zegalogue, dasiglucagon, Status: Opinion

On 30 May 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Zegalogue, intended for the treatment of severe hypoglycaemia in patients …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on May 31, 2024 - 14:36 GMT

Summary of opinion: Tevimbra, 30/05/2024 Positive

On 30 May 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Tevimbra. The marketing authorisation holder for this medicinal …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on May 31, 2024 - 14:36 GMT

Summary of opinion: Livmarli, 30/05/2024 Positive

On 30 May 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Livmarli. The marketing authorisation holder for this medicinal …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on May 31, 2024 - 14:36 GMT

Summary of opinion: Tagrisso, 30/05/2024 Positive

On 30 May 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Tagrisso. The marketing authorisation holder for this medicinal …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on May 31, 2024 - 14:36 GMT

Summary of opinion: Eliquis, 30/05/2024 Positive

On 30 May 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Eliquis. The marketing authorisation holder for this medicinal …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on May 31, 2024 - 14:36 GMT

Summary of opinion: Skyrizi, 30/05/2024 Positive

On 30 May 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Skyrizi. The marketing authorisation holder for this medicinal …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on May 31, 2024 - 14:36 GMT

Withdrawn application: Scenesse, 24/04/2024

Scenesse is a medicine used to treat adults with EPP. In patients with EPP, exposure to light can lead to symptoms such as pain and swelling of the skin, which prevent them from being able to spend time outdoors or in places with bright light. Scenesse is …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on May 31, 2024 - 14:36 GMT

Human medicines European public assessment report (EPAR): Akantior, polihexanide, Status: Opinion

On 30 May 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Akantior1, intended for the treatment of Acanthamoeba keratitis, a severe …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on May 31, 2024 - 14:36 GMT

Human medicines European public assessment report (EPAR): Kinharto, Omecamtiv mecarbil, Date of refusal: 07/05/2024, Status: ...

Based on the review of the data and the company’s response to the Agency’s questions, at the time of the withdrawal, the Agency had concerns and its provisional opinion was that Kinharto could not be authorised for the treatment of chronic (long-term) …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on May 31, 2024 - 14:36 GMT

Human medicines European public assessment report (EPAR): Pomalidomide Krka, pomalidomide, Status: Opinion

On 30 May 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Pomalidomide Krka, intended for the treatment of multiple myeloma. The …

Distribution channels: Healthcare & Pharmaceuticals Industry